Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus host disease; and Irpagratinib (ABSK011), a small-molecule inhibitor of FGFR4, which is in pivotal stage and Phase Ib/II for the treatment of hepatocellular carcinoma. It also engages in the development of ABSK061, which is in Phase Ib/II for the treatment of gastric cancer and achondroplasia; and ABSK043, which is in Phase Ib/II for the treatment of solid tumors and non-small cell lung cancer. In addition, the company develops drugs in Phase I/Ia clinical trial, including ABSK121 for solid tumors; ABSK112 for non-small cell lung and breast cancers; ABK3376 for non-small cell lung cancer; ABSK131 for solid tumors; ABSK141 for solid tumors; and ABSK051 for solid tumors, as well as ABSK012, which is in preclinical stage for the treatment of rhabdomyosarcoma and solid tumors. Further, it is involved in the development of drugs in IND enabling stage, such as ABSK211, ABSK191, and ABSK192 for solid tumors, as well as P151 for cardiometabolic; and drugs in lead optimization stage comprising P011, P018, P020, and P017 for solid tumors, as well as P023 for obesity and P022 for atopic dermatitis, asthma, and chronic obstructive pulmonary disease. Additionally, the company provides advisory and management services. Abbisko Cayman Limited was founded in 2016 and is headquartered in Shanghai, China. Address: Building 3, Shanghai, China